Case Presentation:

A 53 yo male presented to the ER. Relatives claimed that patient was in USOH when he started to ‘convulse’. PMH did not include seizures. Home medication was bupropion, as tobacco cessation treatment.

Pt appeared disoriented, being a*o*1, and slow to answer questions. He was not recognizing family and was very paranoid. (Pt’s baseline was a*o*3 with nl affect.) Otherwise, neurological exam was grossly nonfocal. Labs included a nl SMA7. WBC was 16.9 K/ul (nl 4.5‐10.8) with a left shift of 85.8 (nl 40‐74). UA was wnl. CXR showed no infiltrate. Drug tox was negative, specifically including benzos (Bzs). HCT revealed gen cortical and cerebellar atrophy. The LP CSF fluid was colorless with 3 WBC’s, 298 RBC’s, 46 protein (12‐60) and 74 glucose (nl 40‐70). India Ink and bacterial antigens were negative.

Pt was admitted to medicine for encephalopathy. Neurology and ID were consulted. MRI showed a 1‐2 mm subacute subdural hematoma which was unlikely to be causing the pt’s symptoms. An EEG was not feasible. During hospitalization, the patient was alert but highly anxious/ paranoid with visual hallucinations. Security had to be called often, as the pt attacked several staff members. HIV testing was negative as were Syphilis, Lyme, HSV, Rabies, porphyria, paraneoplastic and West Nile. TSH, B12, Folate were wnl. Psychiatry was now called. Pt was transferred to MICU for observational care. The pt began tx for Bz withdrawal and his mental status returned to baseline. Upon regaining luceny, pt admitted to Alprazolam abuse for self‐treatment of insomnia and that he had recently ran out of his supply.

Discussion:

Pt was successfully treated for Bz withdrawal due to the clinical presentation of delirium, a convulsion and hostile behavior, even though there was no initial hx of Bz use and the Bz urine tox was negative.

Alprazolam has two major metabolites in the plasma: 4‐hydroxyalprazolam and α‐hydroxyalprazolam. A benzophenone derived from Alprazolam is also found which is inactive. Alprazolam has a short half‐life and it is excreted primarily in the urine with its metabolites. Immunoassays use antibodies to detect the presence of specific compounds and may lack sensitivity. Most assays are designed to detect Oxazepam and Desmethyldiazepam which are metabolites for several benzodiazepines. Evidence suggests that compounds with various differences in chemical structure such as Midazolam, Lorazepam or Clonazepam may not be reliably detected, leading to false‐negative results. This may also be the case for Alprazolam and its metabolites. Furthermore, Bzs with short half‐lives might not be identified if enough time elapses since last use.

Conclusions:

Benzodiazepine urine toxicology may be misleading. Consider treatment for benzodiazepine withdrawal if clinically warranted, even if the Bz urine tox is negative.